平田 賢郎 (ヒラタ ケンロウ)

Hirata, Kenro

写真a

所属(所属キャンパス)

医学部 腫瘍センター (信濃町)

職名

助教(有期)

メールアドレス

メールアドレス

学歴 【 表示 / 非表示

  • 2001年04月
    -
    2007年03月

    慶應義塾, 医学部

    大学

  • 2009年04月
    -
    2013年03月

    慶應義塾, 医学研究科

    大学院, 博士

学位 【 表示 / 非表示

  • 博士(医学), 慶應義塾, 課程, 2014年02月

免許・資格 【 表示 / 非表示

  • 日本内科学会 総合内科専門医, 2019年

  • 日本臨床腫瘍学会 がん薬物療法専門医

  • 日本がん治療認定医機構 がん治療認定医

  • 日本ヘリコバクター学会 H. pylori感染症認定医

  • 日本肝臓学会 肝臓専門医

全件表示 >>

 

研究分野 【 表示 / 非表示

  • 消化器内科学

研究キーワード 【 表示 / 非表示

  • 消化器系悪性腫瘍

  • 胃癌

  • 食道癌

 

論文 【 表示 / 非表示

  • Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group

    Hirata K., Hamamoto Y., Ando M., Imamura C.K., Yoshimura K., Yamazaki K., Hironaka S., Muro K.

    BMC cancer (BMC cancer)  20 ( 1 )  2020年06月

     概要を見る

    BACKGROUND: Ramucirumab (RAM) with weekly paclitaxel (wPTX) is a standard second-line therapy for advanced or recurrent gastric cancer. Nanoparticle albumin-bound paclitaxel (nab-PTX), an albumin-bound form of PTX, was developed to improve the therapeutic index of taxane treatment. However, the ABSOLUTE trial showed the non-inferiority of weekly nab-PTX (w-nab-PTX) to wPTX with respect to overall survival (OS) as second-line therapy for advanced or recurrent gastric cancer, and subgroup analysis of patients with peritoneal dissemination showed favourable OS and progression-free survival (PFS) in the w-nab-PTX arm compared to those in the wPTX arm. This study evaluated whether w-nab-PTX plus RAM is more effective than wPTX plus RAM for patients with peritoneal dissemination. METHODS: The P-SELECT trial (WJOG10617G) is a prospective, open-label, multicentre, randomised phase II study evaluating wPTX plus RAM (arm A) versus w-nab-PTX plus RAM (arm B). Key eligibility criteria include the following: 1) histologically proven adenocarcinoma, 2) unresectable or recurrent gastric cancer, 3) peritoneal dissemination, 4) intolerance or refractory to first-line therapy including fluoropyrimidines, and 5) ECOG Performance Status (PS) 0-2. Patients are randomised to either arm at a 1:1 ratio stratified by institution, PS, and severity of ascites. PTX (80 mg/m2; days 1, 8, and 15) and RAM (8 mg/kg; days 1 and 15) are administered every 4 weeks in arm A, while nab-PTX (100 mg/m2; days 1, 8, and 15) instead of PTX is administered in arm B. The primary endpoint is OS, and the main secondary endpoints are PFS, objective response rate, safety, neuropathy-specific quality of life, and biomarkers. To maintain a probability of ≥70% to ensure the hazard ratio for OS in arm B is lower than 0.90, 105 subjects are required. The study was initiated in October 2018 and is being conducted in 58 centres of the West Japan Oncology Group. DISCUSSION: The results of this study will determine whether w-nab-PTX plus RAM has the potential to be a preferred therapeutic option for advanced and recurrent gastric cancer with peritoneal dissemination, compared to wPTX plus RAM. TRIAL REGISTRATION: This study was prospectively registered in the Japan Registry of Clinical Trials (jRCTs031180022, October 1, 2018).

  • Clinical and Endoscopic Characteristics of Pyogenic Granuloma in the Small Intestine: A Case Series with Literature Review

    Hayashi Y., Hosoe N., Takabayashi K., Kamiya K.J.L., Mutaguchi M., Miyanaga R., Hirata K., Fukuhara S., Mikami Y., Sujino T., Masugi Y., Naganuma M., Ogata H., Kanai T.

    Internal medicine (Tokyo, Japan) (Internal medicine (Tokyo, Japan))  59 ( 4 ) 501 - 505 2020年02月

    ISSN  09182918

     概要を見る

    Pyogenic granuloma (PG) generally appears in the skin or oral cavity, but rarely occurs in the small intestine, where it can cause bleeding. To date, only 35 cases of small intestinal PG have been reported in the English literature. We retrospectively collected information from the clinical records of seven cases of small intestinal PG that were managed in our hospital and summarized the characteristics. Further information on the clinical characteristics was obtained from the literature. Capsule endoscopy, useful for identifying the source of hemorrhage in obscure gastrointestinal bleeding, can detect PGs. Treatment can often be accomplished with endoscopic mucosal resection.

  • Pancreatic fat content may increase the risk of imaging progression in low-risk branch duct intraductal papillary mucinous neoplasm

    Kashiwagi K., Minami K., Seino T., Hirata K., Iwasaki E., Inoue N., Iwao Y., Kanai T.

    Journal of Digestive Diseases (Journal of Digestive Diseases)  20 ( 10 ) 557 - 562 2019年10月

    ISSN  17512972

     概要を見る

    © 2019 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd Objective: To identify risk factors of imaging progression (increase in cyst size or main pancreatic duct size, or a new mural nodule) in low-risk branch duct intraductal papillary mucinous neoplasm (BD-IPMN), including obesity-related factors such as pancreatic fat content. Methods: Our hospital databases were searched for patients who had completed health checkup, including upper abdominal magnetic resonance imaging (MRI) over 48 months (August 2012 to July 2016). Individuals with BD-IPMN without worrisome features and high-risk stigmata who underwent surveillance with at least one follow-up MRI, irrespective of the follow-up period, were included. Pancreatic computed tomography attenuation indexes were defined as the difference between the pancreas and spleen attenuation (P - S) and the pancreas to spleen attenuation ratio (P/S). Results: Among 75 patients diagnosed as having low-risk BD-IPMN, during a median follow-up of 36 months, 11 (15%) had imaging progression in cyst size, including two with worrisome features. A multivariate logistic analysis showed that the initial cyst size and both indexes (P - S, or P/S) were significantly associated with imaging progression in IPMN, respectively (Model 1: odds ratio [OR] 1.188, 95% confidence interval [CI] 1.060-1.331, P = 0.003; OR 0.871, 95% CI 0.776-0.977, P = 0.019; Model 2: OR 1.186, 95% CI 1.064-1.322, P = 0.002; OR 0.002, 95% CI 0.000-0.970, P = 0.049). Conclusions: Pancreatic fat content and initial cyst size were significantly associated with imaging progression in low-risk BD-IPMN. Revisions of international consensus Fukuoka guidelines might be customized based on initial cyst size and pancreatic fat content.

  • Unmet needs of cancer patients with chemotherapy-related hand-foot syndrome and targeted therapy-related hand-foot skin reaction: A qualitative study

    Komatsu H., Yagasaki K., Hirata K., Hamamoto Y.

    European Journal of Oncology Nursing (European Journal of Oncology Nursing)  38   65 - 69 2019年02月

    ISSN  14623889

     概要を見る

    © 2018 Purpose: The objective of this qualitative study was to understand the perceived needs of advanced-stage cancer patients with chemotherapy-related hand-foot syndrome (HFS) and/or targeted therapy-related hand-foot skin reaction (HFSR). Method: Face-to-face interviews were conducted with 20 outpatients with advanced/recurrent cancer and chemotherapy-related HFS and/or targeted therapy-related HFSR using a semi-structured interview guide at Keio University Hospital, Tokyo, Japan. Thematic analysis was used to analyse the data. Results: The unmet needs of cancer patients with chemotherapy-related HFS and/or targeted therapy-related HFSR was identified through four themes: a sense of helplessness with persistent symptoms, noticeable appearance as a barrier to social participation, decreased willingness to work and continue treatment, and need of individual coping strategies. Conclusion: This study revealed unmet needs of cancer patients with chemotherapy-related HFS and/or targeted therapy-related HFSR that are not often voiced. Health care providers should provide full information in advance and find the best coping strategy for individual patients.

  • 集学的治療を要する頸部食道がん

    平田 賢郎

    内科 123 ( 4 ) 549 - 550 2019年

    研究論文(学術雑誌), 単著, 査読無し

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

研究発表 【 表示 / 非表示

  • Randomized phase II trial of weekly paclitaxel + ramucirumab versus weekly nab-paclitaxel + ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy: WJOG10617G/P-SELECT.

    Kenro Hirata, Yasuo Hamamoto, Kenji Tsuchihashi, Chihiro Kondoh, Kentaro Yamazaki, Shuichi Hironaka, Masahiko Ando, Chiyo K Imamura, Kenichi Yoshimura, Kei Muro

    The European Society for Medical Oncology Cancer Congress 2019, 2019年09月, ポスター(一般)

  • 咽頭メラノーシスの視認は上気道消化管新生物予測に有用である

    平田 賢郎

    第15回日本臨床腫瘍学会学術集会, 2017年07月

  • Soft palatal melanosis as a predictor for neoplasia in the upper aerodigestive tract.

    平田 賢郎

    American Society of Clinical Oncology 2017, 2017年06月

  • 上気道消化管新生物予測における咽頭メラノーシスの有用性の検討

    平田 賢郎

    アルコール医学生物学研究会, 2017年01月, 口頭(一般)

  • ダクラタスビル・アスナプレビル療法における肝機能障害の検討

    平田 賢郎

    ウイルス肝炎学術講演会, 2014年12月

全件表示 >>

競争的資金等の研究課題 【 表示 / 非表示

  • Vulnerable高齢食道扁平上皮癌患者に対する標準治療の確立

    2020年04月
    -
    2023年03月

    平田 賢郎, 補助金,  代表

  • WJOG10617G フッ化ピリミジン系薬剤を含む一次治療に不応・不耐となった腹膜播種を有する切除不能の進行・再発胃/食道胃接合部腺癌に対するweekly PTX+ramucirumab療法とweekly nab-PTX+ramucirumab療法のランダム化第II相試験(P-SELECT試験)

    2018年10月
    -
    2023年09月

    平田 賢郎, 補助金,  代表

  • 標準療法不耐の高齢食道癌患者に対するオーダーメイド医療の基盤構築

    2016年04月
    -
    2020年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 平田 賢郎, 基盤研究(C), 補助金,  代表

  • ピロリ菌感染時における十二指腸上皮細胞の鉄吸収異常と鉄毒性に関する検討

    2011年
    -
    2012年

    補助金,  代表

  • ヒト鉄代謝ホルモンヘプシジンに注目したHelicobacter pylori感染十二指腸上皮細胞における鉄吸収システムの変化

    2010年
    -
    2011年

    平田 賢郎, 補助金,  代表

全件表示 >>

受賞 【 表示 / 非表示

  • J-HOPE award

    2019年03月, The University of Texas MD Anderson Cancer Center

    受賞区分: 出版社・新聞社・財団等の賞

  • 内科学教室同窓会 松木康夫賞

    2018年06月

  • 第8回 ICAT publication award

    2013年12月

  • 第7回 ICAT award 最優秀賞

    2012年12月

  • サイトプロテクション研究会奨励賞

    2012年03月

 

担当授業科目 【 表示 / 非表示

  • 医学概論

    2020年度, 春学期, 専門科目, 講義, 専任

  • 医学概論

    2019年度, 春学期, 専門科目, 講義, 専任

  • 医学概論

    2018年度, 春学期, 専門科目, 講義, 専任

 

社会活動 【 表示 / 非表示

  • 特定臨床研究への対応の実際

    西日本がん研究機構(WJOG)

    2020年05月
  • 大阪オンコロジーセミナー Meeting the Cancer Experts 2020 食道癌

    西日本がん研究機構(WJOG)

    2020年04月
  • 特定臨床研究への対応の実際

    西日本がん研究機構(WJOG)

    2019年

委員歴 【 表示 / 非表示

  • 2019年
    -
    継続中

    食道癌診療ガイドライン システマティックレビュアー

  • 2019年
    -
    継続中

    JCOG(日本臨床腫瘍研究グループ)食道がんグループ 医学審査員

  • 2019年
    -
    継続中

    西日本がん研究機構(WJOG)臓器横断的ワーキンググループ 委員

  • 2019年
    -
    継続中

    胃癌治療ガイドライン システマティックレビュアー

  • 2018年
    -
    継続中

    西日本がん研究機構(WJOG)消化器グループ 若手会FLAG 代表委員, WJOG(西日本がん研究機構)